PPARγ-gene therapy using an adenovirus vector for inflammatory bowel disease

Folia Pharmacologica Japonica

Volumn 122, Issue 4, 2003, Pages 309-316

  Nakajima, Atsushi ^a   Katayama, Kazufumi ^b   Mayumi, Tadanori ^b  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Gene therapy; Inflammatory bowel disease; PPAR

Indexed keywords

ADENOVIRUS VECTOR; CELL NUCLEUS RECEPTOR; CYCLOOXYGENASE 2; DEXTRAN SULFATE; INTERCELLULAR ADHESION MOLECULE 1; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REGULATOR PROTEIN; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CELL DIFFERENTIATION; CONTROLLED STUDY; CROHN DISEASE; DIGESTIVE SYSTEM INFLAMMATION; DISEASE MODEL; DRUG EFFECT; ENTERITIS; INSULIN SENSITIVITY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; TISSUE LEVEL; ULCERATIVE COLITIS; VIRAL GENE THERAPY; VIRUS REPLICATION;

EID: 0142056005     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.122.309     Document Type: Review

References (21)

1. Blumberg RS, Strober W. Prospects for research in inflammatory bowel disease. JAMA. 2001;285:643-647.
2. Su CG, Wen X, Bailey ST, et al. A novel therapy for colitis utilizing PPARγ ligands to inhibit the epithelial inflammatory response. J Clin Invest. 1999;104:383-389.
3. Nakajima A, Wada K, Miki H, et al. Endogenous PPARγ mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology. 2001;120:460-469.
4. Wada K, Nakajima A, Blumberg RS. PPAR gamma and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohn's disease. Trends Mol Med. 2001;7:329-331.
5. Desreumaux P, Dubuquoy L, Nutten S, et al. Attenuation of colon inflammation through activators of the retinoid X receptor (RXR)/peroxisome proliferator-activated receptor gamma (PPARgamma) heterodimer. A basis for new therapeutic strategies. J Exp Med. 2001;193:827-838.
6. Saubermann LJ, Nakajima A, Wada K, et al. PPARgamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis. Inflamm Bowel Dis. 2002;8:330-339.
7. Hafraoui S, Lefebvre AM, Geboes K, et al. Ulcerative colitis is associated with a mucosal deficit in PPARgamma. Gastroenterology. 2001;116 (Suppl): A689.
8. Katayama K, Wada K, Nakajima A, et al. A novel PPARγ gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. Gastroenterology. 2003;124:1315-1324.
9. Braissant O, Wahli W. Differential expression of peroxisome proliferator-activated receptor -alpha, -beta, and -gamma during rat embryonic development. Endocrinology. 1998;139:2748-2754.
10. Saez E, Tontonoz P, Nelson MC, et al. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med. 1998;4:1058-1061.
11. Michalik L, Wahli W. Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions. Curr Opin Biotechnol. 1999;10:564-570.
12. Lewis JD, Lichtenstein GR, Stein RB, et al. An open-label trial of the PPARγ ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol. 2001;96:3323-3328.
13. Mizuguchi H, Kay MA. A simple method for constructing E1- and E1/E4-deleted recombinant adenoviral vectors. Hum Gene Ther. 1999;10:2013-2017.
14. Mizuguchi H, Koizumi N, Hosono T, et al. A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. Gene Ther. 2001;8: 730-735.
15. Okada N, Tsukada K, Nakagawa S, et al. Efficient gene delivery into dendritic cells by fiber-mutant adenovirus vectors. Biochem Biophys Res Commun. 2001;282:173-179.
16. Nakajima A, Wada K, Katayama K, et al. Gene expression profile after peroxisome proliferator-activated receptor-g ligand administration in dextran sodium sulfate mice. J Gastroenterol. 2002;37 Suppl:62-67.
17. Shanahan F. Inflammatory bowel disease: immunodiagnosis, immunotherapeutics, and ecotherapeutics. Gastroenterology. 2001;120:622-635.
18. Khandoudi N, Delerive P, Berrebi-Bertrand I, et al. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH (2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes. 2002;51:1507-1514.
19. Shiomi T, Tsutsui H, Hayashidani S, et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2002;106:3126-3132.
20. Wayman NS, Hattori Y, McDonald MC, et al. Ligands of peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J. 2002;16:1027-1040.